Long-Term Remissions in First Group of Patients to Receive Personalized Cellular Therapy for CLL
September 03, 2015
A Science Translational Medicine report details the mature results from the initial CAR T cell trial for Chronic Lymphocytic Leukemia (CLL) at Penn. For eight of 14 patients, CAR T cell persistence correlated with clinical responses, with some complete remissions continuing past four and a half years. No patient with CLL who achieved complete remission relapsed, and no minimal residual disease was detected.
Read the Department of Communications news release.